

2014

Identification of low molecular weight compounds inhibiting growth of Corynebacteria: potential lead compounds for antibiotics

Jaime L. Stark
University of Nebraska-Lincoln

Jennifer C. Copeland
University of Nebraska-Lincoln

Alexander Eletsky
The State University of New York at Buffalo

Greg A. Somerville
University of Nebraska-Lincoln, gsomerville3@unl.edu

Thomas Szyperski
The State University of New York at Buffalo

See next page for additional authors

Follow this and additional works at: <http://digitalcommons.unl.edu/chemistrypowers>

Stark, Jaime L.; Copeland, Jennifer C.; Eletsky, Alexander; Somerville, Greg A.; Szyperski, Thomas; and Powers, Robert, "Identification of low molecular weight compounds inhibiting growth of Corynebacteria: potential lead compounds for antibiotics" (2014). *Robert Powers Publications*. 67.
<http://digitalcommons.unl.edu/chemistrypowers/67>

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Robert Powers Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Jaime L. Stark, Jennifer C. Copeland, Alexander Eletsy, Greg A. Somerville, Thomas Szyperski, and Robert Powers



Published in final edited form as:

ChemMedChem. 2014 February ; 9(2): 282–285. doi:10.1002/cmdc.201300386.

Identification of low molecular weight compounds inhibiting growth of Corynebacteria: potential lead compounds for antibiotics

Dr. Jaime L. Stark^[a], Dr. Jennifer C. Copeland^[a], Dr. Alexander Eletsky^[b], Prof. Greg A. Somerville^[c], Prof. Thomas Szyperski^[b], and Prof. Robert Powers^{*,[a]}

^[a]Department of Chemistry University of Nebraska-Lincoln Lincoln, NE, 68588-0304

^[b]Department of Chemistry The State University of New York at Buffalo Buffalo, NY 14260

^[c]School of Veterinary Medicine and Biomedical Sciences University of Nebraska-Lincoln Lincoln, NE, 68588-0905

Keywords

Antibiotics; Corynebacteria; Drug Discovery; FAST-NMR; NMR Spectroscopy

The genus *Corynebacterium* consists of nearly seventy species and is closely related to the genera *Mycobacterium*, *Nocardia*, and *Rhodococcus*. The characteristic traits of Corynebacteria include cells that are shaped like straight rods with clubbed ends, as well as an extra cell wall layer consisting of mycolic acids covalently bound to the peptidoglycan layer which adds an additional layer of protection against antibiotics. Corynebacteria are very well studied and outstandingly important for the large scale biotechnological production of amino acids and nucleotides.^[1] Moreover, Corynebacteria produce several pathogens that affect humans and livestock. Toxins produced by *C. diphtheriae* and *C. ulcerans* cause diphtheria, a highly contagious respiratory infection in humans,^[2] or diphtheria-like symptoms,^[2–3] respectively. *C. pseudotuberculosis* causes “cheesy gland” disease in goats and sheep resulting in significant economic losses.^[2, 4] Moreover, while rare, many other Corynebacteria species have also been shown to cause infections. Therefore, elucidating the functional roles of uncharacterized proteins from Corynebacteria is of high biomedical and economic importance.

Protein CG2496 from *Corynebacterium glutamicum* (UniProtKB ID: Q6M3G5, Q8NNC9; Gene ID: CG2496, Cgl2275) is predicted to be an integral membrane protein comprised of 684 amino acids, where the N-terminal and C-terminal polypeptide segments relative to a single transmembrane helix are extracellular and cytoplasmic, respectively. In the NCBI RefSeq and UniProtKB^[5] databases, CG2496 is annotated as a chromosome segregation ATPase, but there is currently no experimental evidence for this particular annotation. Homologous proteins are found in genomes of 43 other species of Corynebacteria. A significant portion of the N-terminal domain of CG2496 (residues 63–171) belongs to the TPM domain (named after proteins TLP18.3, Psb32 and MOLO-1) family (Pfam^[6] accession: PF04536), which currently contains 3,085 protein sequences from 1,821 species, including bacteria, plants, protozoa and lower metazoa, such as nematodes and lancelets. Two TPM domain-containing proteins, TLP18.3 from *A. thaliana* and Psb32(SII1390) from

*Corresponding author Fax: (402) 472-9402 rpowers3@unl.edu.

Supporting information for this article is available on the WWW under <http://www.chemmedchem.org> or from the author.

Synechocystis sp., were shown to be involved in the photosystem II (PSII) repair cycle.^[7] Phosphatase activity was reported for TLP18.3,^[7b] however, the measured enzymatic activity levels were very low. In *C. elegans*, the TPM domain protein MOLO-1 acts as a modulator of the levamisole-sensitive acetylcholine receptor (L-AChR), but the function of TPM domain proteins in other organisms is still unknown. The Northeast Structural Genomics Consortium (NESG; <http://www.nesg.org>) recently determined the solution NMR structure^[8] of the TPM domain of CG2496 comprising residues 41-180 (PDB ID: 2KPT; NESG target ID: CgR26A) which revealed a distinct architecture and provided the first structural representative for PF04536.

Here we describe the identification of low molecular weight compounds binding to the extracellular N-terminal domain of protein CG2496 from *C. glutamicum* using an NMR-based screening approach (FAST-NMR).^[9] We expect that the newly identified compounds will also support future functional characterization of protein CG2496. Furthermore, assuming that protein CG2496 plays an important role for proliferation of *C. glutamicum*, we investigated to which extent one of the compounds, that is, methiothepin, inhibits cell growth.

1D ¹H NMR screening of the FAST-NMR library of 460 low molecular weight compounds resulted in 13 initial hits which showed broadening of ¹H NMR peaks in the presence of CG2496(41-180) (Table 1). Specific interaction with CG2496(41-180) was revealed by assessing chemical shift perturbations in 2D [¹⁵N,¹H]-HSQC spectra recorded for CG2496(41-180) in the presence of each of the 13 compounds. Additionally, 5 more compounds from the library, which did not show line-broadening in the 1D ¹H NMR screen, were evaluated using the 2D [¹⁵N,¹H]-HSQC screen. These compounds were selected to test hypotheses of CG2496(41-180) function. Of the 18 total compounds screened by 2D [¹⁵N,¹H]-HSQC, 10 induced minor perturbations of a small number (<7) of 2D [¹⁵N,¹H]-HSQC peaks. Only one compound, methiothepin, induced a significant number (~25) of chemical shift perturbations in the 2D [¹⁵N,¹H]-HSQC spectrum of CG2496(41-180) (Figure 1). An NMR titration of CG2496(41-180) with methiothepin determined a dissociation constant (K_D) of $54 \pm 19 \mu\text{M}$. Intriguingly, residues exhibiting significant chemical shift perturbations upon the binding of methiothepin are strongly conserved within the TPM domain family and are part of a mostly neutral and hydrophobic surface cleft (Figure 2), which was previously predicted as the putative active site.^[8] Every compound that induced a chemical shift perturbation in the 2D [¹⁵N,¹H]-HSQC showed a perturbation for Asp56, while 10 of 11 of these compounds showed perturbations for Tyr53. These two residues are also found in the predicted active site. Notably, methiothepin is a serotonin receptor antagonist commonly used as an United States food and drug administration (FDA) approved antipsychotic drug.^[10]

Despite the available three-dimensional structure and similarity with TPM domains of known function, the function of the CG2496(41-180) domain remains unknown. Sequence similarity searches with BlastP^[11] identify only uncharacterized proteins from Corynebacteria, while searches for structurally similar proteins with PDBeFold^[12] and DALI^[13] identify several phosphatases and the C-terminal domain of an alanyl-tRNA synthetase. However, our binding results did not indicate any interaction with typical phosphatase substrates, such as O-phospho-L-serine. The STRING^[14] database indicates relationships with primarily hypothetical proteins, however a gene encoding a dGTP hydrolase and a gene encoding a histone N-acetyltransferase are loosely associated with CG2496(41-180). Furthermore, a comparison of the CG2496(41-180)-methiothepin binding site to a database of protein-ligand binding sites using CPASS^[15] did not result in any hits above a 30% similarity threshold, which is the minimum score used to consider two proteins to have structurally and functionally similar binding sites.^[15b]

Next, assuming that protein CG2496 plays an important role for *C. glutamicum*, we investigated if methiothepin inhibits cell growth. A disk diffusion assay (Figure 3) shows that methiothepin does indeed inhibit the growth of *C. glutamicum*. Additionally, a comparative minimum inhibitory concentration (MIC) test for methiothepin was performed for *C. glutamicum* and *S. aureus*, which does not possess a homolog of CG2496. *C. glutamicum* can only grow in media with up to 20 mM methiothepin. Conversely, *S. aureus* is able to grow at higher methiothepin concentrations of at least 40 mM. The low solubility of methiothepin in complex cell culture media prevented the use of higher concentrations and the determination of a reliable MIC value. However, the growth inhibition of *C. glutamicum* by methiothepin and the corresponding lack of activity against *S. aureus* suggests CG2496 is the *in vivo* target of methiothepin. Correspondingly, methiothepin would be expected to be active against other Corynebacteria containing a homolog of CG2496.

A tiered ligand-affinity screen using the FAST-NMR approach revealed that methiothepin, an FDA approved drug, binds to CG2496(41-180) and also inhibits the growth of *C. glutamicum*. The presence of CG2496 homologs in *Corynebacterium* spp. pathogens (e.g., the genomes of *C. ulcerans*, *C. diphtheriae*, and *C. pseudotuberculosis* encode homologs of CG2496 with 46%, 38%, and 43% sequence identity, respectively) suggests that methiothepin may bind to these proteins as well and may also act as an antibiotic for these species. These results identify the functionally uncharacterized CG2496 protein and its homologs as novel targets for drug discovery, and methiothepin as a potentially a lead compound to develop a new line of antibiotics against Corynebacteria.

Experimental Section

Details of the FAST-NMR ligand affinity screens, the CG2496(41-180)-methiothepin NMR titration experiment, the generation of the of CG2496(41-180)-methiothepin complex structure, and the disk diffusion assay are provided in the Supporting Information.

Acknowledgments

This work was supported by the National Institute of Allergy and Infectious Diseases [grant number R21AI081154] as well as by a grant from the Nebraska Tobacco Settlement Biomedical Research Development Funds to RP, the National Institute of Allergy and Infectious Diseases [grant number AI087668] to GAS and RP, funds provided through the Hatch Act to the University of Nebraska Institute of Agriculture and Natural Resources to GAS, and the Protein Structure Initiative of the National Institutes of Health [grant number U54 GM094597] to TS. The research was performed in facilities renovated with support from the National Institutes of Health [grant number RR015468-01].

References

- [1]. Schneider J, Wendisch VF. Appl Microbiol Biotechnol. 2011; 91:17–30. [PubMed: 21552989]
- [2]. Bernard K. J Clin Microbiol. 2012; 50:3152–3158. [PubMed: 22837327]
- [3]. Trost E, Al-Dilaimi A, Papavasiliou P, Schneider J, Viehoveer P, Burkovski A, Soares SC, Almeida SS, Dorella FA, Miyoshi A, Azevedo V, Schneider MP, Silva A, Santos CS, Santos LS, Sabbadini P, Dias AA, Hirata R Jr, Mattos-Guaraldi AL, Tauch A. BMC Genomics. 2011; 12:383. [PubMed: 21801446]
- [4]. Dorella FA, Pacheco LG, Oliveira SC, Miyoshi A, Azevedo V. Vet Res. 2006; 37:201–218. [PubMed: 16472520]
- [5]. UniProt Consortium. Nucleic Acids Res. 2012; 40:D71–75. [PubMed: 22102590]
- [6]. Punta M, Coghill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L, Sonnhammer EL, Eddy SR, Bateman A, Finn RD. Nucleic Acids Res. 2012; 40:D290–301. [PubMed: 22127870]

- [7]. a) Sirpio S, Allahverdiyeva Y, Suorsa M, Paakkanen V, Vainonen J, Battchikova N, Aro EM. *Biochem J.* 2007; 406:415–425. [PubMed: 17576201] b) Wu HY, Liu MS, Lin TP, Cheng YS. *Plant Physiol.* 2011; 157:1015–1025. [PubMed: 21908686] c) Wegener KM, Bennewitz S, Oelmuller R, Pakrasi HB. *Mol Plant.* 2011; 4:1052–1061. [PubMed: 21653280]
- [8]. Eletsky A, Acton TB, Xiao R, Everett JK, Montelione GT, Szyperski T. *J Struct Funct Genomics.* 2012; 13:9–14. [PubMed: 22198206]
- [9]. a) Mercier KA, Baran M, Ramanathan V, Revesz P, Xiao R, Montelione GT, Powers R. *J. Amer. Chem. Soc.* 2006; 128:15292–15299. [PubMed: 17117882] b) Fischer JJ, Jardetzky O. *J. Amer. Chem. Soc.* 1965; 87:3237–3244. [PubMed: 14329431] c) Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. *Science.* 1996; 274:1531–1534. [PubMed: 8929414]
- [10]. a) Dall'Olio R, Vaccheri A, Montanaro N. *Pharmacol Biochem Behav.* 1985; 23:43–48. [PubMed: 2994121] b) Monachon MA, Burkard WP, Jalfre M, Haefely W. *Naunyn Schmiedebergs Arch Pharmacol.* 1972; 274:192–197. [PubMed: 4340797]
- [11]. a) Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. *J Mol Biol.* 1990; 215:403–410. [PubMed: 2231712] b) Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. *Nucleic Acids Res.* 1997; 25:3389–3402. [PubMed: 9254694]
- [12]. Krissinel E, Henrick K. *Acta Crystallogr D Biol Crystallogr.* 2004; 60:2256–2268. [PubMed: 15572779]
- [13]. Holm L, Rosenstrom P. *Nucleic Acids Res.* 2010; 38:W545–549. [PubMed: 20457744]
- [14]. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ. *Nucleic Acids Res.* 2013; 41:D808–815. [PubMed: 23203871]
- [15]. a) Powers R, Copeland JC, Germer K, Mercier KA, Ramanathan V, Revesz P. *Proteins.* 2006; 65:124–135. [PubMed: 16862592] b) Powers R, Copeland JC, Stark JL, Caprez A, Guru A, Swanson D. *BMC Res Notes.* 2011; 4:17. [PubMed: 21269480]
- [16]. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N. *Nucleic Acids Res.* 2010; 38:W529–533. [PubMed: 20478830]
- [17]. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. *J Comput Chem.* 2004; 25:1605–1612. [PubMed: 15264254]
- [18]. Honig B, Nicholls A. *Science.* 1995; 268:1144–1149. [PubMed: 7761829]




Figure 1. An overlay of 2D [^{15}N , ^1H]-HSQC spectra of free CG2496(41-180) (black) and CG2496(41-180) bound with methiothepin (gray). The chemical structure of methiothepin is displayed in the lower right.




Figure 2.

a) The CG2496(41-180)-methiothepin complex generated by AutoDock where residues with significant chemical shift perturbations are colored red. b) ConSurf^[16] residue conservation surface representation of the CG2496(41-180)-methiothepin complex where highly conserved residues are magenta and poorly conserved residues are cyan. c) UCSF Chimera^[17] hydrophobicity surface representation of the CG2496(41-180)-methiothepin complex where the hydrophilic surface is blue and hydrophobic surface is orange. d) Delphi^[18] electrostatics surface representation of the CG2496(41-180)-methiothepin complex where the positively-charged surface is blue and negatively-charged surface is red.




Figure 3. Disk diffusion assay. *C. glutamicum* was plated and grown in the presence of a) a disk soaked with water and b) a disk soaked with an aqueous solution containing 400 μM methiothepin.

Table 1

List of compounds from the FAST-NMR screen that bind CG2496(41-180)

Compound Name	1D Hits ^a	2D Hits ^b	Perturbed Residues ^c
N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide	X	X	Y53, N56, V168
4-methylpyrazole	X	X	Y53, N56, V168
Bay 11-708	X	X	Y53, N56, V168
histamine	X	X	Y53, N56, V168
methiothepin	X	X	Y44, L46, Y53, N56, T58, G62, V79, V90, D96, T104, N111, G112, G114, V116
adenine	X	X	Y53, N56
1-methylimidazole	X	X	Y53, N56, V168
ethacridine	X	X	L46, Y53, N56, T58, F149, L162, V168
adenosine-5'-triphosphate ^d		X	N56, T58
serotonin ^d		X	Y53, N56, T58
adenosine-5'-monophosphate ^d		X	Y53, N56, V168

^aIndicates compounds that exhibited line broadening in 1D ¹H NMR screen in the presence of CG2496(41-180)

^bIndicates compounds that caused peak perturbations in the 2D [¹H, ¹⁵N]-HSQC of CG2496(41-180)

^cIdentity of the residues that were significantly perturbed (>1 standard deviation from mean perturbation) in the 2D [¹H, ¹⁵N]-HSQC of CG2496(41-180)

^dThese compounds were evaluated in the 1D ¹H NMR screen but exhibited no line broadening. Evaluated in 2D [¹H, ¹⁵N]-HSQC screen to test potential CG2496(41-180) functions.